Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Casgevy (exa-cel)
Pharma
Vertex gains FDA expansion of Casgevy to those ages 2 and older
The FDA has granted a label expansion for children ages 2 and up to receive Vertex's gene therapy Casgevy for sickle cell disease or beta thalassemia.
Kevin Dunleavy
Jul 6, 2026 11:30am
Vertex sets lofty $500M revenue goal for new products in '26
Feb 13, 2026 12:02pm
As Vertex's pain launch gains more use, sales just missed in Q3
Nov 4, 2025 8:40am
UPDATED: Most expensive drugs in the US in 2025
Aug 11, 2025 3:00am
Vertex's proposed fertility support program shot down in court
Apr 1, 2025 11:48am
Vertex's Casgevy breaks ground with 1st commercial infusions
Nov 5, 2024 12:19pm
